Biogen Idec, Inc. (Massachusetts) Reports Second Quarter 2005 Results

CAMBRIDGE, Mass., July 26 /PRNewswire-FirstCall/ -- Biogen Idec Inc. , a global biotechnology leader with leading products and capabilities in oncology, neurology and immunology, today reported its second quarter 2005 results.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031112/LAW121LOGO ) Second Quarter Highlights * Total revenues grew 12% to $606 million vs. prior year $539 million, driven primarily by AVONEX(R) (Interferon beta-1a) worldwide sales up 10% to $382 million and RITUXAN(R) (rituximab) revenues from the joint business arrangement up 22% to $185 million. * On a reported basis, calculated in accordance with U.S. generally accepted accounting principles (GAAP), second quarter earnings per share (EPS) were $0.10. Excluding merger-related accounting impacts of $86 million and charges of $78 million related to the sale of the NIMO manufacturing facility, adjusted non-GAAP EPS were $0.43, representing a 26% increase. * $20 million of charges, or EPS of $0.04, were included in both the GAAP and adjusted non-GAAP results related to TYSABRI(R) (natalizumab) inventories that were written off during the quarter.

"Impressive results from AVONEX and RITUXAN, coupled with operational discipline and effective cost management, drove an increase of more than 20% in earnings," said James Mullen, Biogen Idec's Chief Executive Officer. "We have also maintained our strong commitment to the MS community by conducting an extensive safety evaluation of TYSABRI which is ongoing. We look forward to the expected completion of the evaluation by the end of the summer and to further discussions with the regulatory authorities regarding the path forward for TYSABRI."

Financial Performance

On an adjusted non-GAAP basis, Biogen Idec's net income grew 22% to $149 million in the second quarter of 2005 (Q2 2004 adjusted non-GAAP: $122 million). Adjusted non-GAAP EPS were $0.43 for the second quarter of 2005 (Q2 2004 adjusted non-GAAP: $0.34).

On a reported basis, calculated in accordance with GAAP, Biogen Idec reported net income of $35 million (or EPS of $0.10) in the second quarter of 2005 (Q2 2004: net income of $0.8 million, or EPS of $0.00). The difference between adjusted non-GAAP net income and EPS and GAAP net income and EPS in the second quarter were primarily due to:

* pre-tax charges of $86 million of non-cash merger-related accounting impacts, primarily amortization of intangibles, inventory step-up, and other merger-related charges, and * charges totaling approximately $78 million related to the sale of the NIMO manufacturing facility. These adjustments are itemized on Table 3. Revenue Performance

Revenues for the second quarter of 2005 were up 22% to $185 million (Q2 2004: $151 million) from Biogen Idec's joint business arrangement with Genentech related to RITUXAN, a treatment for certain B-cell non-Hodgkin's lymphomas (NHL) that Biogen Idec co-promotes in the U.S. with Genentech. All U.S. sales of RITUXAN are recognized by Genentech, and Biogen Idec records its share of the pretax co-promotion profits on a quarterly basis. U.S. net sales of RITUXAN were $450 million in the second quarter of 2005 (Q2 2004: $390 million), as reported by Genentech.

Revenues from AVONEX, Biogen Idec's therapy for patients with relapsing forms of multiple sclerosis (MS), increased 10% in the second quarter to $382 million (Q2 2004: $347 million). AVONEX, the leading therapy for MS in the U.S. as measured by revenues, patients, and total prescriptions, recorded sales of $230 million in U.S. sales for the quarter (Q2 2004: $227 million). International sales increased 27% to $152 million in the second quarter of 2005 (Q2 2004: $120 million).

Table 4 provides individual product revenues.

Royalties were $22 million in the second quarter of 2005 (Q2 2004: $24 million).

Second Quarter Events * On April 6, 2005, Biogen Idec, Genentech and Roche announced that a Phase III clinical study of RITUXAN met its primary endpoint of a greater proportion of RITUXAN-treated patients achieving an American College of Rheumatology (ACR) 20 response at week 24, compared to placebo. In the second half of this year, Biogen Idec and Genentech expect to submit a supplemental filing for approval of RITUXAN in the U.S. for patients with active rheumatoid arthritis (RA) who are inadequate responders to anti-TNF therapies. The filing will be largely based on the results of the Phase III study. * On April 12, 2005, at the 57th annual American Academy of Neurology (AAN) meeting in Miami Beach, FL, the two-year data from the AFFIRM Phase III monotherapy trial was presented. AFFIRM met all primary and secondary endpoints, including disability progression and relapse rate. TYSABRI treatment led to a 42 percent reduction in the risk of disability progression compared to placebo. TYSABRI also reduced the rate of clinical relapses by 67 percent compared to placebo, which was sustained and consistent with the previously reported one-year results. * On May 17, 2005, Biogen Idec announced that its scientists have identified a molecule in the central nervous system (CNS) that may play a pivotal role in CNS repair and regeneration. The research, published in the June 2005 edition of Nature Neuroscience, is the first to suggest a role for LINGO-1 in nerve repair and could lead to potential pathways for treating MS and other demyelinating diseases. * On June 9, 2005, Biogen Idec, Genentech, and Roche announced preliminary positive results from a large randomized clinical trial (DANCER) of RITUXAN in RA showing that a greater proportion of patients treated with a single course of RITUXAN, with a stable dose of methotrexate, achieved ACR 20, 50 and 70 response rates compared to placebo. * On June 14, 2005, Biogen Idec announced that a Phase II clinical study showed that galiximab (anti-CD80 mAb) may be used in combination with RITUXAN, and the combination may prolong event-free survival in patients with relapsed or refractory, follicular NHL when compared to previous results with RITUXAN monotherapy. Side effects of the combination were similar to treatment with RITUXAN alone. * On June 30, 2005, Biogen Idec and Elan announced that ENCORE, the second Phase III induction trial of TYSABRI for the treatment of moderately to severely active Crohn's disease in patients with evidence of active inflammation, met the primary endpoint of clinical response as defined by a 70 point decrease in baseline Crohn's Disease Activity Index (CDAI) score at both weeks 8 and 12. * In June, Biogen Idec agreed to sell the NIMO Oceanside, California biologics manufacturing facility to Genentech for $408 million. The approximately 430 employees at the facility were offered employment at Genentech or retained by Biogen Idec. Biogen Idec incurred charges totaling approximately $78 million related to the sale. Conference Call and Webcast

The Company's earnings conference call for the second quarter will be broadcast via the internet at 5:00 p.m. ET on July 26, 2005, and will be accessible through the investor relations section of Biogen Idec's homepage, http://www.biogenidec.com.

About Biogen Idec

Biogen Idec creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit http://www.biogenidec.com.

Safe Harbor

This press release contains forward-looking statements regarding expected future financial results, plans for our development programs, the potential for TYSABRI and the completion of the TYSABRI safety evaluation.

These statements are based on the Company's current beliefs and expectations. A number of risks and uncertainties could cause actual results to differ materially. For example, financial results, and other statements regarding future financial performance, and overall prospects for the Company's products may be affected by a number of factors, including any unexpected slowing of growth of the markets for AVONEX and RITUXAN, any change in market acceptance of AVONEX and RITUXAN in key markets worldwide, the impact of reimbursement and pricing decisions related to the Company's products, the impact of competitive products on the Company's products, any material decreases in sales by licensees of products on which the Company receives royalties, the impact of litigation, the impact of costs related to the suspension of TYSABRI, increases in costs related to in-licensing and product opportunities, increases in costs related to development of new products and existing products in new indications, and any material issues, delays or failures related to the manufacturing or supply of the Company's products.

Our long-term growth will depend on the successful development and commercialization of new products. Drug development involves a high degree of risk. For example, the plans for our development programs could be negatively affected if unexpected concerns arise from additional data or analysis, if regulatory authorities require additional information or further studies, or if we were to encounter other unexpected hurdles.

The potential for TYSABRI is subject to a number of risks and uncertainties. There is no assurance, for example, that we will be able to gain sufficient information to fully understand the risks associated with the product. There is also no assurance that the Company and Elan will be able to resume marketing and sales of TYSABRI. The completion of the TYSABRI safety evaluation is also subject to a number of risks and uncertainties, including the difficulty of analyzing complex data and results, and unanticipated logistical hurdles.

For more detailed information on the risks and uncertainties associated with these forward looking statements and the Company's other activities, see the periodic reports filed by the Company with the Securities and Exchange Commission. The Company does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media Contact: Jose Juves Associate Director, Public Affairs Biogen Idec Tel: (617) 914-6524 Investment Community Contact: Elizabeth Woo Vice President, Investor Relations Biogen Idec Tel: (617) 679-2812 TABLE 1 Financial Results For The Second Quarter of 2005 Condensed Consolidated Statements Of Income - GAAP Basis (in thousands, except per share amounts) Three Months Ended Six Months Ended June 30, June 30, 2005 2004 2005 2004 REVENUES Product $398,822 $363,186 $796,406 $735,723 Unconsolidated joint business 184,934 151,157 345,387 285,112 Royalties 21,734 24,297 48,483 49,510 Corporate partner 144 123 3,160 10,160 Total revenues 605,634 538,763 1,193,436 1,080,505 COST AND EXPENSES Cost of product and royalty revenues 71,093 151,729 170,701 406,496 Research and development 179,843 169,782 358,611 328,702 Selling, general and administrative 155,754 139,414 314,227 270,474 Amortization of acquired intangible assets 77,078 79,308 152,756 160,168 Loss on Sale of Plant 75,565 - 75,565 - Total cost and expenses 559,333 540,233 1,071,860 1,165,840 Income (loss) from operations 46,301 (1,470) 121,576 (85,335) Other income/ (expense), net 6,051 6,413 (2,874) 18,139 INCOME (LOSS) BEFORE INCOME TAXES 52,352 4,943 118,702 (67,196) Income taxes (benefit) 17,848 4,116 40,738 (26,825) NET INCOME $34,504 $827 $77,964 $(40,371) BASIC EARNINGS (LOSS) PER SHARE $0.10 $0.00 $0.23 (0.12) DILUTED EARNINGS (LOSS) PER SHARE $0.10 $0.00 $0.23 (0.12) SHARES USED IN CALCULATING: BASIC EARNINGS PER SHARE 332,629 337,018 333,946 336,084 DILUTED EARNINGS PER SHARE 344,735 350,279 348,086 336,084 TABLE 2 Condensed Consolidated Balance Sheets (dollars in thousands) Jun. 30, 2005 Dec. 31, 2004 Assets: Current assets Cash, cash equivalents and securities available-for-sale $927,453 $1,057,942 Accounts receivable, net 254,014 278,637 Inventory 243,538 251,016 Other current assets 371,297 343,449 Total current assets 1,796,302 1,931,044 Long-term securities available- for-sale 873,182 1,109,624 Property and equipment, net 1,150,420 1,525,225 Intangible assets, net 3,139,315 3,292,827 Goodwill 1,151,105 1,151,105 Other 157,828 155,933 Total assets $8,268,152 $9,165,758 Liabilities and shareholders' equity Current liabilities $540,653 $1,260,748 Long-term deferred tax liability 882,021 921,771 Non-current liabilities 99,664 156,838 Shareholders' equity 6,745,814 6,826,401 Total liabilities and shareholders' equity $8,268,152 $9,165,758 TABLE 3 Financial Results For The Second Quarter of 2005 Condensed Consolidated Statements Of Income - Operating Basis (in millions, except per share amounts)

The non-GAAP financial measures presented below are utilized by Biogen Idec management to gain an understanding of the comparative financial performance of the Company. Management believes that the non-GAAP financial measures are useful because they exclude those non-operational activities or transactions that are not necessarily relevant to understanding the trends of the Company or the prospects of future performance. The presentation of this information is not meant to be considered in isolation or as a substitute for GAAP financial measures. Numbers may not foot due to rounding.

Three Months Ended Six Months Ended June 30, June 30, 2005 2004 2005 2004 Earnings per share - Diluted: GAAP $0.10 $0.00 $0.23 ($0.12) Adjusted Pro Forma (Non-GAAP) $0.43 $0.34 $0.73 $0.73 AN ITEMIZED RECONCILIATION BETWEEN NET INCOME ON A GAAP BASIS AND NET INCOME ON A NON-GAAP BASIS IS AS FOLLOWS: GAAP Net Income/(Loss) $34.5 $0.8 $78.0 ($40.4) COGS: Fair value step up of inventory acquired from former Biogen, Inc 9.0 93.4 18.3 287.8 R&D: Costs associated with Sale of Oceanside Manufacturing Facility 1.9 - 1.9 - R&D: Merger related and purchase accounting costs - 0.7 - 2.9 SG&A: Merger related and purchase accounting costs - 0.6 0.4 5.0 Purchase accounting: Amortization of acquired intangible assets related to the merger with former Biogen, Inc. 77.1 79.3 152.8 160.2 Loss on Sale of Oceanside Manufacturing Facility 75.6 - 75.6 - Income taxes: Income tax effect of reconciling items (49.0) (53.2) (72.1) (151.2) Non-GAAP Net Income $149.0 $121.7 $254.8 $264.3

Adjustments were made to conform prior periods to current year presentation including adoption of EITF 03-06, which requires allocation of income to certain holders of equity and debt instruments.

Table 4 Biogen Idec Inc Product Revenues for Second Quarter 2005 (in thousands) Three Months Ended June 30, 2005 2004 PRODUCT REVENUES Avonex(R) $381,789 $346,516 Amevive(R) 12,456 12,116 Tysabri(R) (897) - Zevalin(R) 5,474 4,554 Total Product Revenues $398,822 $363,186 Six Months Ended June 30, 2005 2004 PRODUCT REVENUES Avonex(R) $755,374 $701,234 Amevive(R) 24,473 25,103 Tysabri(R) 5,049 - Zevalin(R) 11,510 9,386 Total Product Revenues $796,406 $735,723

Photo: http://www.newscom.com/cgi-bin/prnh/20031112/LAW121LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk; photodesk@prnewswire.comBiogen Idec Inc.

CONTACT: Media Contact: Jose Juves, Associate Director, Public Affairs,+1-617-914-6524, or Investment Community Contact: Elizabeth Woo, VicePresident, Investor Relations, +1-617-679-2812, both of Biogen Idec

Back to news